HUMA — Humacyte Income Statement
0.000.00%
Last trade - 00:00- $203.21m
- $174.81m
Annual income statement for Humacyte, fiscal year end - December 31st, USD millions except per share, conversion factor applied.
2020 December 31st | 2021 December 31st | 2022 December 31st | 2023 December 31st | 2024 December 31st | |
|---|---|---|---|---|---|
| Period Length: | 12 M | 12 M | 12 M | 12 M | 12 M |
| Source: | PROSPECTUS | 10-K | 10-K | 10-K | 10-K |
| Standards: | USG | USG | USG | USG | USG |
| Status: | Final | Final | Final | Final | Final |
| Revenue | |||||
| Total Revenue | 1.49 | 1.26 | 1.56 | 0 | 0 |
| Selling / General / Administrative Expenses | |||||
| Research And Development | |||||
| Unusual Expense / Income | |||||
| Total Operating Expenses | 66.1 | 79.2 | 86.1 | 99.4 | 114 |
| Operating Profit | -64.6 | -77.9 | -84.6 | -99.4 | -114 |
| Total Net Non Operating Interest Income / Expense | |||||
| Other Net Non Operating Costs | |||||
| Net Income Before Taxes | -66.5 | -26.5 | -12 | -111 | -149 |
| Provision for Income Taxes | |||||
| Net Income After Taxes | -66.5 | -26.5 | -12 | -111 | -149 |
| Net Income Before Extraordinary Items | |||||
| Net Income | -66.5 | -26.5 | -12 | -111 | -149 |
| Income Available to Common Shareholders Excluding Extraordinary Items | |||||
| Income Available to Common Shareholders Including Extraordinary Items | |||||
| Diluted Net Income | -66.5 | -26.5 | -12 | -111 | -149 |
| Diluted Weighted Average Shares | |||||
| Basic EPS Including Extraordinary Items | |||||
| Diluted EPS Including Extraordinary Items | |||||
| Diluted EPS Excluding Extraordinary Items | |||||
| Normalised Income Before Taxes | |||||
| Normalised Income After Taxes | |||||
| Normalised Income Available to Common Shareholders | |||||
| Diluted Normalised EPS | -0.646 | -0.289 | -0.116 | -1.08 | -1.26 |
| Dividends per Share |